Cargando…
Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker
Aims: Metabolic and structural perturbations in skeletal muscle have been found in patients with heart failure (HF) both with preserved (HFpEF) and reduced (HFrEF) ejection fraction in association with reduced muscle endurance (RME). We aimed in the current study to create phenotypes for patients wi...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139290/ https://www.ncbi.nlm.nih.gov/pubmed/35626711 http://dx.doi.org/10.3390/cells11101674 |
_version_ | 1784714824587935744 |
---|---|
author | Bekfani, Tarek Bekhite, Mohamed Neugebauer, Sophie Derlien, Steffen Hamadanchi, Ali Nisser, Jenny Hilse, Marion S. Haase, Daniela Kretzschmar, Tom Wu, Mei-Fang Lichtenauer, Michael Kiehntopf, Michael von Haehling, Stephan Schlattmann, Peter Lehmann, Gabriele Franz, Marcus Möbius-Winkler, Sven Schulze, Christian |
author_facet | Bekfani, Tarek Bekhite, Mohamed Neugebauer, Sophie Derlien, Steffen Hamadanchi, Ali Nisser, Jenny Hilse, Marion S. Haase, Daniela Kretzschmar, Tom Wu, Mei-Fang Lichtenauer, Michael Kiehntopf, Michael von Haehling, Stephan Schlattmann, Peter Lehmann, Gabriele Franz, Marcus Möbius-Winkler, Sven Schulze, Christian |
author_sort | Bekfani, Tarek |
collection | PubMed |
description | Aims: Metabolic and structural perturbations in skeletal muscle have been found in patients with heart failure (HF) both with preserved (HFpEF) and reduced (HFrEF) ejection fraction in association with reduced muscle endurance (RME). We aimed in the current study to create phenotypes for patients with RME and HFpEF compared to RME HFrEF according to their metabolomic profiles and to test the potential of Kynurenine (Kyn) as a marker for RME. Methods: Altogether, 18 HFrEF, 17 HFpEF, and 20 healthy controls (HC) were prospectively included in the current study. The following tests were performed on all participants: isokinetic muscle function tests, echocardiography, spiroergometry, and varied blood tests. Liquid chromatography tandem mass spectrometry was used to quantify metabolites in serum. Results: Except for aromatic and branched amino acids (AA), patients with HF showed reduced AAs compared to HC. Further perturbations were elevated concentrations of Kyn and acylcarnitines (ACs) in HFpEF and HFrEF patients (p < 0.05). While patients with HFpEF and RME presented with reduced concentrations of ACs (long- and medium-chains), those with HFrEF and RME had distorted AAs metabolism (p < 0.05). With an area under the curve (AUC) of 0.83, Kyn shows potential as a marker in HF and RME (specificity 70%, sensitivity 83%). In a multiple regression model consisting of short-chain-ACs, spermine, ornithine, glutamate, and Kyn, the latest was an independent predictor for RME (95% CI: −13.01, −3.30, B: −8.2 per 1 µM increase, p = 0.001). Conclusions: RME in patients with HFpEF vs. HFrEF proved to have different metabolomic profiles suggesting varied pathophysiology. Kyn might be a promising biomarker for patients with HF and RME. |
format | Online Article Text |
id | pubmed-9139290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91392902022-05-28 Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker Bekfani, Tarek Bekhite, Mohamed Neugebauer, Sophie Derlien, Steffen Hamadanchi, Ali Nisser, Jenny Hilse, Marion S. Haase, Daniela Kretzschmar, Tom Wu, Mei-Fang Lichtenauer, Michael Kiehntopf, Michael von Haehling, Stephan Schlattmann, Peter Lehmann, Gabriele Franz, Marcus Möbius-Winkler, Sven Schulze, Christian Cells Article Aims: Metabolic and structural perturbations in skeletal muscle have been found in patients with heart failure (HF) both with preserved (HFpEF) and reduced (HFrEF) ejection fraction in association with reduced muscle endurance (RME). We aimed in the current study to create phenotypes for patients with RME and HFpEF compared to RME HFrEF according to their metabolomic profiles and to test the potential of Kynurenine (Kyn) as a marker for RME. Methods: Altogether, 18 HFrEF, 17 HFpEF, and 20 healthy controls (HC) were prospectively included in the current study. The following tests were performed on all participants: isokinetic muscle function tests, echocardiography, spiroergometry, and varied blood tests. Liquid chromatography tandem mass spectrometry was used to quantify metabolites in serum. Results: Except for aromatic and branched amino acids (AA), patients with HF showed reduced AAs compared to HC. Further perturbations were elevated concentrations of Kyn and acylcarnitines (ACs) in HFpEF and HFrEF patients (p < 0.05). While patients with HFpEF and RME presented with reduced concentrations of ACs (long- and medium-chains), those with HFrEF and RME had distorted AAs metabolism (p < 0.05). With an area under the curve (AUC) of 0.83, Kyn shows potential as a marker in HF and RME (specificity 70%, sensitivity 83%). In a multiple regression model consisting of short-chain-ACs, spermine, ornithine, glutamate, and Kyn, the latest was an independent predictor for RME (95% CI: −13.01, −3.30, B: −8.2 per 1 µM increase, p = 0.001). Conclusions: RME in patients with HFpEF vs. HFrEF proved to have different metabolomic profiles suggesting varied pathophysiology. Kyn might be a promising biomarker for patients with HF and RME. MDPI 2022-05-18 /pmc/articles/PMC9139290/ /pubmed/35626711 http://dx.doi.org/10.3390/cells11101674 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bekfani, Tarek Bekhite, Mohamed Neugebauer, Sophie Derlien, Steffen Hamadanchi, Ali Nisser, Jenny Hilse, Marion S. Haase, Daniela Kretzschmar, Tom Wu, Mei-Fang Lichtenauer, Michael Kiehntopf, Michael von Haehling, Stephan Schlattmann, Peter Lehmann, Gabriele Franz, Marcus Möbius-Winkler, Sven Schulze, Christian Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker |
title | Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker |
title_full | Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker |
title_fullStr | Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker |
title_full_unstemmed | Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker |
title_short | Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker |
title_sort | metabolomic profiling in patients with heart failure and exercise intolerance: kynurenine as a potential biomarker |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139290/ https://www.ncbi.nlm.nih.gov/pubmed/35626711 http://dx.doi.org/10.3390/cells11101674 |
work_keys_str_mv | AT bekfanitarek metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT bekhitemohamed metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT neugebauersophie metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT derliensteffen metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT hamadanchiali metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT nisserjenny metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT hilsemarions metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT haasedaniela metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT kretzschmartom metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT wumeifang metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT lichtenauermichael metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT kiehntopfmichael metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT vonhaehlingstephan metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT schlattmannpeter metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT lehmanngabriele metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT franzmarcus metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT mobiuswinklersven metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker AT schulzechristian metabolomicprofilinginpatientswithheartfailureandexerciseintolerancekynurenineasapotentialbiomarker |